Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for -Amplified Tumors With -D1228X or -Y1230X Mutations.
作者信息
Piper-Vallillo Andrew J, Kobayashi Susumu S, Costa Daniel B
机构信息
Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
出版信息
JTO Clin Res Rep. 2021 Mar 16;2(3):100133. doi: 10.1016/j.jtocrr.2020.100133. eCollection 2021 Mar.
Abstract
摘要
相似文献
1
Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for -Amplified Tumors With -D1228X or -Y1230X Mutations.携带G1228X或Y1230X突变的MET扩增肿瘤对不同类别MET抑制剂的耐药和敏感差异模式。
JTO Clin Res Rep. 2021 Mar 16;2(3):100133. doi: 10.1016/j.jtocrr.2020.100133. eCollection 2021 Mar.
2
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.福雷替尼可克服 MET 外显子 14 跳跃突变的 NSCLC 患者接受卡马替尼/替泊替尼治疗后的常见靶标耐药突变。
J Hematol Oncol. 2022 Jun 11;15(1):79. doi: 10.1186/s13045-022-01299-z.
3
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in -Amplified Gastric Cancer.选择性MET抑制剂赛沃替尼在MET扩增型胃癌中获得性耐药的机制
JCO Precis Oncol. 2020 Mar 24;4. doi: 10.1200/PO.19.00386. eCollection 2020.
4
Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.MET扩增的ALK阳性肺癌中的分子异质性和共同改变基因：对MET靶向治疗的意义。
Lung Cancer. 2023 Dec;186:107383. doi: 10.1016/j.lungcan.2023.107383. Epub 2023 Sep 23.
5
MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription.MET 抑制通过抑制 AP-1 介导的转录下调获得性 EGFR 抑制剂耐药的 MET 扩增肺癌细胞中 DR4 的表达。
Neoplasia. 2021 Aug;23(8):766-774. doi: 10.1016/j.neo.2021.06.006. Epub 2021 Jul 4.
6
MEK inhibitors against MET-amplified non-small cell lung cancer.针对MET扩增的非小细胞肺癌的MEK抑制剂
Int J Oncol. 2016 Dec;49(6):2236-2244. doi: 10.3892/ijo.2016.3736. Epub 2016 Oct 17.
7
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.MET IHC 作为一种筛选肺腺癌 MET 扩增或 MET 外显子 14 突变的方法并不理想：来自肺癌突变联盟的三机构队列研究的数据。
J Thorac Oncol. 2019 Sep;14(9):1666-1671. doi: 10.1016/j.jtho.2019.06.009. Epub 2019 Jun 20.
8
Overexpression of contributes to inherent resistance to MET inhibitors in -amplified patient-derived gastric cancer xenografts.在MET扩增的患者来源的胃癌异种移植模型中，[具体基因]的过表达导致对MET抑制剂的固有抗性。 （注：原文中“Overexpression of ”后面缺少具体基因名称）
Oncol Lett. 2015 Oct;10(4):2003-2008. doi: 10.3892/ol.2015.3601. Epub 2015 Aug 12.
9
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.肺癌中 MET 外显子 14 突变对 8 种 MET 酪氨酸激酶抑制剂的敏感性和耐药性的体外研究。
J Thorac Oncol. 2019 Oct;14(10):1753-1765. doi: 10.1016/j.jtho.2019.06.023. Epub 2019 Jul 3.
10
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.重新审视 MET：局部晚期或转移性、MET 扩增的胃食管癌症患者的临床特征和治疗结果。
Oncologist. 2020 Nov;25(11):e1691-e1700. doi: 10.1634/theoncologist.2020-0274. Epub 2020 Sep 12.
本文引用的文献
1
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor.MET酪氨酸激酶抑制剂的获得性耐药机制
JTO Clin Res Rep. 2021 Mar 16;2(3):100134. doi: 10.1016/j.jtocrr.2020.100134. eCollection 2021 Mar.
2
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by -D1228 and -Y1230 Mutations in -Mutated -Amplified Lung Cancer.在EGFR突变且扩增的肺癌中，奥希替尼联合赛沃替尼的获得性耐药由EGFR的D1228和Y1230突变介导。
JTO Clin Res Rep. 2020 Nov 1;1(4):100071. doi: 10.1016/j.jtocrr.2020.100071. Epub 2020 Jun 20.
3
Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer.卡马替尼治疗外显子 14 突变或扩增的非小细胞肺癌。
N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787.
4
Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.特泊替尼治疗伴有外显子 14 跳跃突变的非小细胞肺癌。
N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29.
5
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.克唑替尼治疗含有 MET 外显子 14 改变的肺癌的抗肿瘤活性。
Nat Med. 2020 Jan;26(1):47-51. doi: 10.1038/s41591-019-0716-8. Epub 2020 Jan 13.
Zotero 插件